Stephen Todd

List of Publications by Year
in descending order

49 papers	**11,219** citations	236925 **25** h-index	197818 **49** g-index
57 all docs	**57** docs citations	**57** times ranked	**15394** citing authors

#	Article	IF	Citations
1	Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nature Genetics, 2013, 45, 1452-1458.	21.4	3,741
2	Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nature Genetics, 2009, 41, 1088-1093.	21.4	2,697
3	Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nature Genetics, 2011, 43, 429-435.	21.4	1,708
4	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	21.4	783
5	Genetic Evidence Implicates the Immune System and Cholesterol Metabolism in the Aetiology of Alzheimer's Disease. PLoS ONE, 2010, 5, e13950.	2.5	347
6	Survival in dementia and predictors of mortality: a review. International Journal of Geriatric Psychiatry, 2013, 28, 1109-1124.	2.7	278
7	Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. The Cochrane Library, 2009, , CD004034.	2.8	185
8	Convergent genetic and expression data implicate immunity in Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 658-671.	0.8	173
9	Gene-Wide Analysis Detects Two New Susceptibility Genes for Alzheimer's Disease. PLoS ONE, 2014, 9, e94661.	2.5	155
10	Inflammation and Anti-Inflammatory Strategies for Alzheimer's Disease â€“ A Mini-Review. Gerontology, 2010, 56, 3-14.	2.8	102
11	Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. , 2006, , CD004034.		73
12	A practical computerized decision support system for predicting the severity of Alzheimer's disease of an individual. Expert Systems With Applications, 2019, 130, 157-171.	7.6	73
13	Platelet Î²-secretase activity is increased in Alzheimer's disease. Neurobiology of Aging, 2008, 29, 661-668.	3.1	70
14	A Multiple Indicators Multiple Causes (MIMIC) model of Behavioural and Psychological Symptoms in Dementia (BPSD). Neurobiology of Aging, 2011, 32, 434-442.	3.1	64
15	Expression and activity of Î²-site amyloid precursor protein cleaving enzyme in Alzheimer's disease. Biochemical Society Transactions, 2005, 33, 1096.	3.4	61
16	Shared genetic contribution to ischemic stroke and Alzheimer's disease. Annals of Neurology, 2016, 79, 739-747.	5.3	56
17	The Role of Variation at AÎ²PP, PSEN1, PSEN2, and MAPT in Late Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 28, 377-387.	2.6	53
18	Concordant Association of Insulin Degrading Enzyme Gene (IDE) Variants with IDE mRNA, AÃŸ, and Alzheimer's Disease. PLoS ONE, 2010, 5, e8764.	2.5	48

#	Article	IF	Citations
19	The development of effective biomarkers for Alzheimer's disease: a review. International Journal of Geriatric Psychiatry, 2013, 28, 331-340.	2.7	46
20	Views of Caregivers on the Ethics of Assistive Technology Used for Home Surveillance of People Living with Dementia. Neuroethics, 2017, 10, 255-266.	2.8	41
21	ABCA7 p.G215S as potential protective factor for Alzheimer's disease. Neurobiology of Aging, 2016, 46, 235.e1-235.e9.	3.1	37
22	A novel reciprocal and biphasic relationship between membrane cholesterol and β€secretase activity in SH€SY5Y cells and in human platelets. Journal of Neurochemistry, 2009, 108, 341-349.	3.9	35
23	Cause of death in Alzheimer's disease: a cohort study. QJM - Monthly Journal of the Association of Physicians, 2013, 106, 747-753.	0.5	33
24	Genetic Variation in the α7 Nicotinic Acetylcholine Receptor is Associated with Delusional Symptoms in Alzheimer's Disease. NeuroMolecular Medicine, 2008, 10, 377-384.	3.4	32
25	Polygenic risk score in postmortem diagnosed sporadic early-onset Alzheimer's disease. Neurobiology of Aging, 2018, 62, 244.e1-244.e8.	3.1	30
26	Plasma Clusterin Levels and the rs11136000 Genotype in Individuals with Mild Cognitive Impairment and Alzheimer's Disease. Current Alzheimer Research, 2013, 10, 973-978.	1.4	28
27	Alzheimer's disease and age-related macular degeneration have different genetic models for complement gene variation. Neurobiology of Aging, 2012, 33, 1843.e9-1843.e17.	3.1	24
28	Shaping a data-driven era in dementia care pathway through computational neurology approaches. BMC Medicine, 2020, 18, 398.	5.5	24
29	Elevated Platelet β-Secretase Activity in Mild Cognitive Impairment. Dementia and Geriatric Cognitive Disorders, 2007, 24, 464-468.	1.5	21
30	Effect of apolipoprotein E and butyrylcholinesterase genotypes on cognitive response to cholinesterase inhibitor treatment at different stages of Alzheimer's disease. Pharmacogenomics Journal, 2011, 11, 444-450.	2.0	21
31	Mutation analysis of sporadic early-onset Alzheimer's disease using the NeuroX array. Neurobiology of Aging, 2017, 49, 215.e1-215.e8.	3.1	21
32	Practical Strategies for Extreme Missing Data Imputation in Dementia Diagnosis. IEEE Journal of Biomedical and Health Informatics, 2022, 26, 818-827.	6.3	18
33	No evidence that extended tracts of homozygosity are associated with Alzheimer's disease. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2011, 156, 764-771.	1.7	17
34	Screening exons 16 and 17 of the amyloid precursor protein gene in sporadic early-onset Alzheimer's disease. Neurobiology of Aging, 2016, 39, 220.e1-220.e7.	3.1	12
35	Alleles that increase risk for type 2 diabetes mellitus are not associated with increased risk for Alzheimer's disease. Neurobiology of Aging, 2014, 35, 2883.e3-2883.e10.	3.1	9
36	The evaluation of a healthcare passport to improve quality of care and communication for people living with dementia (EQuIP): a protocol paper for a qualitative, longitudinal study. BMC Health Services Research, 2016, 16, 363.	2.2	9

#	Article	IF	Citations
37	An Early Stage Researcher's Primer on Systems Medicine Terminology. Network and Systems Medicine, 2021, 4, 2-50.	2.5	9
38	BACE1 Polymorphisms Do Not Influence Platelet Membrane Î²-secretase Activity or Genetic Susceptibility for Alzheimerâ€™s Disease in the Northern Irish Population. NeuroMolecular Medicine, 2008, 10, 368-376.	3.4	8
39	Encouraging lifestyle behaviour change in mild cognitive impairment patients: development of appropriate educational material. Aging and Mental Health, 2013, 17, 276-286.	2.8	8
40	Variation in RTN3 and PPIL2 Genes Does not Influence Platelet Membrane Î²-Secretase Activity or Susceptibility to Alzheimerâ€™s Disease in the Northern Irish Population. NeuroMolecular Medicine, 2009, 11, 337-344.	3.4	7
41	Alzheimerâ€™s Disease Assessments Optimized for Diagnostic Accuracy and Administration Time. IEEE Journal of Translational Engineering in Health and Medicine, 2022, 10, 1-9.	3.7	6
42	Multiâ€timeâ€point data preparation robustly reveals MCI and dementia risk factors. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12116.	2.4	4
43	High-dimensional brain-wide functional connectivity mapping in magnetoencephalography. Journal of Neuroscience Methods, 2021, 348, 108991.	2.5	4
44	Northern Ireland dementia strategy. International Journal of Geriatric Psychiatry, 2010, 25, 902-904.	2.7	3
45	Prevention of dementia by ACE inhibitors and angiotensin receptor blockers - potential but not proven. International Journal of Clinical Practice, 2010, 64, 1595-1598.	1.7	3
46	Acceptability and use of a patient-held communication tool for people living with dementia: a longitudinal qualitative study. BMJ Open, 2020, 10, e036249.	1.9	2
47	Dementia with Lewy bodies. Clinical Medicine, 2019, 19, 430-431.	1.9	1
48	Alzheimer's disease in United Kingdom. European Geriatric Medicine, 2010, 1, 182-185.	2.8	0
49	Can multiple wearable sensors be used to detect the early onset of Parkinson's Disease?. , 2020, , .		0